Telerehabilitation in Distal Radius Fracture
Launched by INSTITUTO MEXICANO DEL SEGURO SOCIAL · Apr 12, 2022
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
Distal radius fractures (DRF) are among the most frequent fractures worldwide; in the United States, they are the second most common fracture in the upper limb, present an estimated annual incidence of 643,000 and represent 1.5% of consultations for hand and forearm fractures in emergency departments, after fractures of the radius and ulna. Their care implies an increase in the cost of care. In the United Kingdom, the National Health Services estimated an average expenditure of £1375.34 per day/patient, with surgical fixation of the FDR; in the USA, the Medicare system estimated a cost of m...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and women older than 15 years
- • With closed distal radius fracture type AO23 A and B
- • Immobilization for six weeks (with or without surgical fixation)
- • With indication by the orthopedic physician to perform rehabilitation
- • Have a cell phone and internet access
- Exclusion Criteria:
- • Patients with distal radius fractures with any of the following radiographic findings: volar tilt \>12°, radial tilt \>23° and radial height \>12 mm
- • Patients with neurological problems, illiteracy, presence of pressure ulcers in the distal third of the forearm or hand that did not heal, users of orally or intravenously administered steroids, patients with pre-existing and concomitant arthritis or osteoarthritis of the wrist, or history of injury. Subjects with less than 80% adherence to treatment were eliminated.
About Instituto Mexicano Del Seguro Social
The Instituto Mexicano del Seguro Social (IMSS) is a prominent public institution in Mexico, dedicated to providing comprehensive healthcare services and social security to its members. Established to enhance public health and welfare, IMSS plays a pivotal role in the advancement of medical research and clinical trials aimed at improving patient outcomes. By facilitating innovative studies, IMSS contributes to the development of new therapies and treatments, ensuring that the healthcare system remains at the forefront of scientific progress and responds effectively to the health needs of the population.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mérida, Yucatán, Mexico
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials